<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02864680</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A00097-38</org_study_id>
    <nct_id>NCT02864680</nct_id>
  </id_info>
  <brief_title>Electrophysiological Study of the Functioning of Magnocellular Visual Pathway in Regular Cannabis Users</brief_title>
  <acronym>CAUSA MAP</acronym>
  <official_title>Electrophysiological Study of the Functioning of Magnocellular Visual Pathway in Regular Cannabis Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the impact of regular use of cannabis on the spatial sensitivity of
      magnocellular system (visual event-related potential, visual ERP).

      Secondary purposes of this study are to evaluate the impact of regular use of cannabis on the
      temporal sensitivity of magnocellular system (visual event-related potential), on the
      dynamics of cortical visual processing during face perception test (visual event-related
      potential) and on functioning of retinal photopic and scotopic systems (electroretinogram).

      The ancillary study is a genetic analysis of a group of candidate genes that aims to identify
      biomarkers for changes in visual processing. This will allow to distinguish among more
      homogeneous and specific groups in future studies on larger cannabis user population. This
      ancillary study concerns all participants subject to their informed consent (facultative
      study).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amplitude of P100 wave in contrast sensibility test</measure>
    <time_frame>up to 1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Culmination time of the P100 wave in contrast sensibility test</measure>
    <time_frame>up to 1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amplitude of P100 wave in visual simultaneity test</measure>
    <time_frame>up to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Culmination time of P100 wave in visual simultaneity test</measure>
    <time_frame>up to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amplitude of P100 wave in face perception test</measure>
    <time_frame>up to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amplitude of N170 wave in face perception test</measure>
    <time_frame>up to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Culmination time of P100 wave in face perception test</measure>
    <time_frame>up to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Culmination time of N170 wave in face perception test</measure>
    <time_frame>up to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amplitude of &quot;a&quot; wave in different ERG sequences</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amplitude of &quot;b&quot; wave in different ERG sequences</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Culmination time of &quot;a&quot; wave in different ERG sequences</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Culmination time of &quot;b&quot; wave in different ERG sequences</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Relationship between variants of candidate genes for alterations of visual treatment and amplitude of P100 wave in contrast sensibility test</measure>
    <time_frame>up to 3 years</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Cannabis Use</condition>
  <arm_group>
    <arm_group_label>Cannabis users</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers, not cannabis/tobacco users</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers, tobacco users</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Schizophrenia patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electroretinography</intervention_name>
    <arm_group_label>Cannabis users</arm_group_label>
    <arm_group_label>Healthy volunteers, not cannabis/tobacco users</arm_group_label>
    <arm_group_label>Healthy volunteers, tobacco users</arm_group_label>
    <arm_group_label>Schizophrenia patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Contrast sensitivity test during Electroencephalography</intervention_name>
    <description>Stimuli are black and white grids, having different range of spatial frequencies, presented with different contrasts on a grey background thanks to a computer monitor, in a dark room. Participants are requested to maintain central fixation. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.</description>
    <arm_group_label>Cannabis users</arm_group_label>
    <arm_group_label>Healthy volunteers, not cannabis/tobacco users</arm_group_label>
    <arm_group_label>Healthy volunteers, tobacco users</arm_group_label>
    <arm_group_label>Schizophrenia patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Visual simultaneity test during Electroencephalography</intervention_name>
    <description>Two vertical bars are showed on a monitor, on the link and right of point of central fixation. Bars appear simultaneously or with a 10 to 200 ms asynchrony. Participants must determine whether stimuli are simultaneous or asynchronous and answer pressing the link button for simultaneity or right button for asynchrony. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.</description>
    <arm_group_label>Cannabis users</arm_group_label>
    <arm_group_label>Healthy volunteers, not cannabis/tobacco users</arm_group_label>
    <arm_group_label>Healthy volunteers, tobacco users</arm_group_label>
    <arm_group_label>Schizophrenia patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Face perception test during Electroencephalography</intervention_name>
    <description>Faces filtered in different spatial frequence ranges are showed randomly on a monitor, in a dark room. Participants must maintain a central fixation thank to a fixation cross. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.</description>
    <arm_group_label>Cannabis users</arm_group_label>
    <arm_group_label>Healthy volunteers, not cannabis/tobacco users</arm_group_label>
    <arm_group_label>Healthy volunteers, tobacco users</arm_group_label>
    <arm_group_label>Schizophrenia patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CAST (cannabis abuse screening test)</intervention_name>
    <arm_group_label>Cannabis users</arm_group_label>
    <arm_group_label>Schizophrenia patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PANSS (Positive And Negative Symptoms Scale) test</intervention_name>
    <arm_group_label>Schizophrenia patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Delayed Matching to Sample (DMS) test</intervention_name>
    <arm_group_label>Cannabis users</arm_group_label>
    <arm_group_label>Healthy volunteers, not cannabis/tobacco users</arm_group_label>
    <arm_group_label>Healthy volunteers, tobacco users</arm_group_label>
    <arm_group_label>Schizophrenia patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Spatial Working Memory (SWM) test</intervention_name>
    <arm_group_label>Cannabis users</arm_group_label>
    <arm_group_label>Healthy volunteers, not cannabis/tobacco users</arm_group_label>
    <arm_group_label>Healthy volunteers, tobacco users</arm_group_label>
    <arm_group_label>Schizophrenia patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rapid Visual Information Processing (RVP) test</intervention_name>
    <arm_group_label>Cannabis users</arm_group_label>
    <arm_group_label>Healthy volunteers, not cannabis/tobacco users</arm_group_label>
    <arm_group_label>Healthy volunteers, tobacco users</arm_group_label>
    <arm_group_label>Schizophrenia patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Test for attentional performance (TAP) / Divided Attention</intervention_name>
    <arm_group_label>Cannabis users</arm_group_label>
    <arm_group_label>Healthy volunteers, not cannabis/tobacco users</arm_group_label>
    <arm_group_label>Healthy volunteers, tobacco users</arm_group_label>
    <arm_group_label>Schizophrenia patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of saliva sample</intervention_name>
    <description>In case of specific consent of participant to ancillary study, for ancillary study</description>
    <arm_group_label>Cannabis users</arm_group_label>
    <arm_group_label>Healthy volunteers, not cannabis/tobacco users</arm_group_label>
    <arm_group_label>Healthy volunteers, tobacco users</arm_group_label>
    <arm_group_label>Schizophrenia patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Affiliation to social security plan

          -  Normal visual acuity or adjusted to normal and normal dilated fundus examination

          -  Signature of informed consent

          -  Cannabis user group: More than 7 cannabis uses per week during the previous month

          -  Cannabis user group: Positive urinary analysis for presence of cannabis

          -  Healthy, non user control group: Absence of cannabis and tobacco use during last 12
             months

          -  Healthy, non user control group: Negative urinary analysis for presence of cannabis

          -  Healthy, non user control group: Age and sex matching with cannabis user group

          -  Healthy, tobacco user control group: Tobacco use from at least 12 months

          -  Healthy, tobacco user control group: Low to very strong addiction to tobacco
             (Fagerström test)

          -  Healthy, tobacco user control group: Absence of cannabis use from more than 12 months

          -  Healthy, tobacco user control group: Negative urinary analysis for presence of
             cannabis

          -  Healthy, tobacco user control group:Age and sex matching with cannabis user group

          -  Schizophrenia patient control group: Schizophrenia according to DMS IV criteria (MINI
             test)

          -  Schizophrenia patient control group: Absence of cannabis use from more than one month
             (regardless of tobacco use)

          -  Schizophrenia patient control group: Negative urinary analysis for presence of
             cannabis

          -  Schizophrenia patient control group: Age and sex matching with cannabis user group

        Exclusion Criteria:

          -  Acute psychiatric pathology (axis I of DSM IV, measured by MINI) except anxiety
             disorder (except schizophrenia group)

          -  Deficiency of the subject making difficult or impossible his/her participation to the
             study or the comprehension of the information

          -  Dyslexia

          -  Addiction to alcohol according to AUDIT scale

          -  Abuse or addiction to other substances according to DSM IV criteria

          -  Acute retinal disorder

          -  Chronic glaucoma

          -  Ophthalmic pathology affecting visual acuity

          -  Current ocular infection

          -  Persons under guardianship, curatorship or judicial protection

          -  Pregnant or breast-feeding women

          -  Persons with life-and-death emergency

          -  Absence of social security plan

          -  Results of preliminary medical examinations incompatible with the study

          -  Simultaneous participation to another therapeutic interventional study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent LAPREVOTE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maison des Addictions - CHU de Nancy, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincent LAPREVOTE</last_name>
    <email>v.laprevote@chu-nancy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maison des Addictions - CHU de Nancy, Hôpital St Julien</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2016</study_first_submitted>
  <study_first_submitted_qc>August 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2016</study_first_posted>
  <last_update_submitted>August 9, 2016</last_update_submitted>
  <last_update_submitted_qc>August 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cannabis</keyword>
  <keyword>magnocellular pathway</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

